RxAnte, a UPMC Enterprises portfolio company that provides patented analytics and targeted clinical programs to improve medication adherence, is experiencing success with its comprehensive pharmacy service for Medicare Advantage Part D (MAPD) health plans, members, and patients.
Six new health plan clients have begun using Mosaic, the pharmacy service RxAnte launched in 2019 to improve medication use, health outcomes, and pharmacy experience in certain Medicare populations. The health plans clients have started referring medically complex members to Mosaic to improve adherence and manage costs of care.
Mosaic uses new technologies to provide home-based services such as analytics-informed medication review and reconciliation, adherence packaging and delivery, and ongoing clinical monitoring for members managing chronic conditions with multiple daily medications.
“Mosaic’s high-touch pharmacy has significantly extended RxAnte’s portfolio of analytics and intervention solutions that outreach to health plan members to improve their outcomes and boost Star Ratings for health plans — positive outcomes UPMC has already experienced from its long partnership with RxAnte,” said Brenton Burns, Executive Vice President of Digital Health & Technology Solutions at UPMC Enterprises.
Added Josh Benner, CEO and co-founder of RxAnte, “I’m especially excited that many of our clients are beginning to adopt our new Mosaic Pharmacy Service for their medically complex and vulnerable populations during the COVID-19 pandemic. We’re seeing promising early impacts on cost of care and pharmacy quality scores, and we look forward to sharing this unique model for pharmacy services with more of our plan partners.”
In addition to the success of Mosaic, RxAnte also is experiencing growth of its flagship analytic solution for MAPD plans. This solution helps plans improve their performance on pharmacy quality measures, including those measures within CMS Star Ratings — an important metric for consumers to assess health plan quality. By prospectively identifying health plan members that are likely to become non-adherent to their medications, RxAnte’s analytic solution improves member medication adherence and ultimately enhances health plans’ performance on critical pharmacy quality measures. This year alone, RxAnte has increased the number of plan member lives under its analytic solution by over 30% to over 14 million Americans.
RxAnte announced this month that clients with four-star ratings entering this performance year improved medication adherence rates by twice as much as their four-star peers, with some contracts improving the percentage of adherent members by as much as 5%.
Additionally, nearly 90% of all quality measures managed by RxAnte are on a multi-year improvement trend, which is critical for plans working to stay above ever-increasing Star Ratings performance thresholds.
Of the MAPD contracts RxAnte managed in both 2018 and 2019, 18% earned higher overall Star Ratings this year; this represents a 13% increase in improvement compared to other MAPD plans in the industry.
Star Ratings, which measure managed care quality and members’ experience with their Medicare Advantage plans, are released annually by the Centers for Medicare and Medicaid Services (CMS) to help consumers compare the nearly 600 Medicare contracts administered by private health plans.
Learn more about RxAnte.